Literature DB >> 29334465

Design of a "Mini" Nucleic Acid Probe for Cooperative Binding of an RNA-Repeated Transcript Associated with Myotonic Dystrophy Type 1.

Wei-Che Hsieh1,2, Raman Bahal1,2, Shivaji A Thadke1,2, Kirti Bhatt1,2, Krzysztof Sobczak1,2, Charles Thornton1,2, Danith H Ly1,2.   

Abstract

Toxic RNAs containing expanded trinucleotide repeats are the cause of many neuromuscular disorders, one being myotonic dystrophy type 1 (DM1). DM1 is triggered by CTG-repeat expansion in the 3'-untranslated region of the DMPK gene, resulting in a toxic gain of RNA function through sequestration of MBNL1 protein, among others. Herein, we report the development of a relatively short miniPEG-γ peptide nucleic acid probe, two triplet repeats in length, containing terminal pyrene moieties, that is capable of binding rCUG repeats in a sequence-specific and selective manner. The newly designed probe can discriminate the pathogenic rCUGexp from the wild-type transcript and disrupt the rCUGexp-MBNL1 complex. The work provides a proof of concept for the development of relatively short nucleic acid probes for targeting RNA-repeat expansions associated with DM1 and other related neuromuscular disorders.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29334465      PMCID: PMC6091549          DOI: 10.1021/acs.biochem.7b01239

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  32 in total

1.  Light-switching excimer probes for rapid protein monitoring in complex biological fluids.

Authors:  Chaoyong James Yang; Steffen Jockusch; Marie Vicens; Nicholas J Turro; Weihong Tan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

2.  Molecular biology. Neutralizing toxic RNA.

Authors:  Thomas A Cooper
Journal:  Science       Date:  2009-07-17       Impact factor: 47.728

Review 3.  Repeat expansion disease: progress and puzzles in disease pathogenesis.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

4.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.

Authors:  J W Miller; C R Urbinati; P Teng-Umnuay; M G Stenberg; B J Byrne; C A Thornton; M S Swanson
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

5.  Precise small-molecule recognition of a toxic CUG RNA repeat expansion.

Authors:  Suzanne G Rzuczek; Lesley A Colgan; Yoshio Nakai; Michael D Cameron; Denis Furling; Ryohei Yasuda; Matthew D Disney
Journal:  Nat Chem Biol       Date:  2016-12-12       Impact factor: 15.040

6.  Pentamidine reverses the splicing defects associated with myotonic dystrophy.

Authors:  M Bryan Warf; Masayuki Nakamori; Catherine M Matthys; Charles A Thornton; J Andrew Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

7.  Studying a Drug-like, RNA-Focused Small Molecule Library Identifies Compounds That Inhibit RNA Toxicity in Myotonic Dystrophy.

Authors:  Suzanne G Rzuczek; Mark R Southern; Matthew D Disney
Journal:  ACS Chem Biol       Date:  2015-09-28       Impact factor: 5.100

8.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

Review 9.  Mangiferin - a bioactive xanthonoid, not only from mango and not just antioxidant.

Authors:  Adam Matkowski; Piotr Kuś; Edyta Góralska; Dorota Woźniak
Journal:  Mini Rev Med Chem       Date:  2013-03       Impact factor: 3.862

10.  Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.

Authors:  Jessica L Childs-Disney; Ewa Stepniak-Konieczna; Tuan Tran; Ilyas Yildirim; HaJeung Park; Catherine Z Chen; Jason Hoskins; Noel Southall; Juan J Marugan; Samarjit Patnaik; Wei Zheng; Chris P Austin; George C Schatz; Krzysztof Sobczak; Charles A Thornton; Matthew D Disney
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  5 in total

1.  Design of Bivalent Nucleic Acid Ligands for Recognition of RNA-Repeated Expansion Associated with Huntington's Disease.

Authors:  Shivaji A Thadke; J Dinithi R Perera; V M Hridya; Kirti Bhatt; Ashif Y Shaikh; Wei-Che Hsieh; Mengshen Chen; Chakicherla Gayathri; Roberto R Gil; Gordon S Rule; Arnab Mukherjee; Charles A Thornton; Danith H Ly
Journal:  Biochemistry       Date:  2018-03-27       Impact factor: 3.162

Review 2.  Perspectives on conformationally constrained peptide nucleic acid (PNA): insights into the structural design, properties and applications.

Authors:  Chaturong Suparpprom; Tirayut Vilaivan
Journal:  RSC Chem Biol       Date:  2022-03-18

Review 3.  Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing.

Authors:  Mariapaola Izzo; Jonathan Battistini; Claudia Provenzano; Fabio Martelli; Beatrice Cardinali; Germana Falcone
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

4.  A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1.

Authors:  Nan Zhang; Brittani Bewick; Guangbin Xia; Denis Furling; Tetsuo Ashizawa
Journal:  Front Genet       Date:  2020-12-10       Impact factor: 4.599

Review 5.  Myotonic dystrophy type 1 drug development: A pipeline toward the market.

Authors:  Marta Pascual-Gilabert; Arturo López-Castel; Ruben Artero
Journal:  Drug Discov Today       Date:  2021-03-31       Impact factor: 7.851

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.